The World Health Organization (WHO) recommended this Friday the use of the antiretroviral drug Paxlovid for those people at high risk who have mild or moderate Covid-19.
PAHO urges to remain alert for the presence of Covid-19
The WHO urges the use of the aforementioned drug for patients with mild or moderate Covid-19 who have a higher risk of promoting serious illness and being hospitalized, as well as for unvaccinated, elderly or immunosuppressed people.
According to a note from the United Nations (UN), this drug was developed by the Pfizer company and is “the best therapeutic option for high-risk patients to date.”
However, the WHO indicated that “the availability, the lack of transparency of the prices in the bilateral agreements made by the producer, and the need to carry out rapid and accurate tests before administering it, are making obtaining this drug a great challenge. for low- and middle-income countries.
Another piece of data that supports the WHO recommendation is that, according to new data from two randomized controlled trials involving more than 3,000 patients, the risk of hospitalization was reduced by 85 percent.
The organization clarified that this drug is not recommended for patients at lower risk, because the benefits were found to be negligible compared to those at higher risk.